MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
MiNK Therapeutics (NASDAQ: INKT) has announced its return to full compliance with Nasdaq Capital Market listing requirements. The company has successfully met both the minimum bid price and market value requirements for continued listing, resolving previous compliance issues.
MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company maintains a pipeline of native and next-generation engineered iNKT programs, with a platform designed for scalable and reproducible manufacturing for off-the-shelf delivery.
MiNK Therapeutics (NASDAQ: INKT) ha annunciato il suo ritorno alla piena conformità con i requisiti di quotazione del Nasdaq Capital Market. L'azienda ha soddisfatto con successo sia i requisiti di prezzo minimo delle azioni che quelli di valore di mercato per la continuazione della quotazione, risolvendo i precedenti problemi di conformità.
MiNK Therapeutics è un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di terapie cellulari T killer naturali invarianti allogeniche (iNKT) per il cancro e le malattie mediate dal sistema immunitario. L'azienda ha un portafoglio di programmi iNKT nativi e di nuova generazione, con una piattaforma progettata per una produzione scalabile e ripetibile per una consegna pronta all'uso.
MiNK Therapeutics (NASDAQ: INKT) ha anunciado su regreso a la plena conformidad con los requisitos de cotización del Nasdaq Capital Market. La compañía ha cumplido con éxito tanto los requisitos de precio mínimo de las acciones como los de valor de mercado para continuar con la cotización, resolviendo así problemas de cumplimiento anteriores.
MiNK Therapeutics es una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias con células T asesinas naturales invariantes alogénicas (iNKT) para el cáncer y enfermedades mediadas por el sistema inmunológico. La empresa mantiene un pipeline de programas iNKT nativos y de próxima generación, con una plataforma diseñada para una fabricación escalable y reproducible para entrega lista para usar.
MiNK Therapeutics (NASDAQ: INKT)는 Nasdaq 자본 시장 상장 요건을 완전히 준수하게 되었다고 발표했습니다. 이 회사는 지속적인 상장을 위한 최소 주가 및 시장 가치 요건을 성공적으로 충족하여 이전의 준수 문제를 해결했습니다.
MiNK Therapeutics는 암 및 면역 매개 질환을 위한 동종 불변 자연 살해 T 세포(iNKT) 치료법 개발에 중점을 둔 임상 단계의 생명공학 회사입니다. 이 회사는 즉시 사용할 수 있는 공급을 위해 확장 가능하고 재현 가능한 제조를 위한 플랫폼을 갖춘 고유 및 차세대 엔지니어링된 iNKT 프로그램의 파이프라인을 유지하고 있습니다.
MiNK Therapeutics (NASDAQ: INKT) a annoncé son retour à la pleine conformité avec les exigences de cotation du Nasdaq Capital Market. L'entreprise a réussi à satisfaire à la fois les exigences de prix minimum des actions et de valeur marchande pour continuer à être cotée, résolvant ainsi les problèmes de conformité précédents.
MiNK Therapeutics est une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires T tueuses naturelles invariantes allogéniques (iNKT) pour le cancer et les maladies médiées par le système immunitaire. L'entreprise maintient un portefeuille de programmes iNKT natifs et de nouvelle génération, avec une plateforme conçue pour une fabrication évolutive et reproductible pour une livraison prête à l'emploi.
MiNK Therapeutics (NASDAQ: INKT) hat die Rückkehr zur vollen Konformität mit den Anforderungen der Nasdaq Capital Market-Listung angekündigt. Das Unternehmen hat erfolgreich sowohl die Anforderungen an den Mindestaktienkurs als auch an den Marktwert für die fortgesetzte Listung erfüllt und damit frühere Compliance-Probleme gelöst.
MiNK Therapeutics ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen invarianten natürlichen Killer-T-Zelltherapien (iNKT) für Krebs und immunvermittelte Erkrankungen konzentriert. Das Unternehmen verfügt über eine Pipeline von nativen und neuartigen iNKT-Programmen, mit einer Plattform, die für eine skalierbare und reproduzierbare Herstellung für die sofortige Lieferung ausgelegt ist.
- Regained full Nasdaq listing compliance, eliminating delisting risk
- Meets both minimum bid price and market value requirements
- None.
Insights
- Enhanced access to institutional investors and improved ability to raise capital through secondary offerings
- Greater trading liquidity and market visibility, essential for attracting long-term investors
- Reduced cost of capital compared to OTC markets
- Stronger positioning for potential strategic partnerships or M&A opportunities
While regaining compliance is positive, it's important to note that MiNK, with a market cap of
The removal of this regulatory overhang should allow management to focus more directly on advancing their clinical programs and business objectives, rather than dealing with listing compliance issues. However, investors should monitor the company's cash position and burn rate, as these factors will be critical for maintaining long-term listing compliance and supporting ongoing clinical development efforts.
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal notice from Nasdaq confirming that the Company has regained compliance with both the minimum bid price and market value of listed securities requirements for continued listing on The Nasdaq Capital Market. As a result, MiNK now meets all Nasdaq Capital Market listing requirements, and the matter has been closed.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the potential and expected benefits of iNKT cell therapies, as well as plans, timelines, and goals for current and future programs. Forward-looking statements are subject to various risks and uncertainties, including those described under “Risk Factors” in the most recent Form 10-K, Form 10-Q, and the S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). Readers are cautioned not to place undue reliance on these statements, which speak only as of the date hereof. MiNK undertakes no obligation to update or revise forward-looking statements except as required by law, and all such statements are expressly qualified by this cautionary statement.
Investor Contact
investor@minktherapeutics.com
Media Contact
communications@minktherapeutics.com
FAQ
What Nasdaq compliance requirements did MiNK Therapeutics (INKT) regain in February 2024?
What is MiNK Therapeutics' (INKT) main therapeutic focus?
What type of manufacturing platform does INKT use for its cell therapies?
What was the significance of INKT's Nasdaq compliance announcement?
